Presence to Precision: Moving beyond Omnichannel - Gurpinder Singh
The pharma industry's legacy is based on constant innovation, particularly in the R&D space. Undoubtedly, science has made strides in treating chronic medical conditions and curing diseases. However, the transition from R&D to commercialization reveals a stark contrast.
For years, Pharma's engagement model has remained stagnant in a world that demands agility and nimbleness. It is necessary to reimagine the customer engagement model to deliver relevant information to the HCPs at the appropriate time and through their preferred channels. Despite the millions of dollars being spent on the commercialization, a significant number of companies continue to use inefficient go-to-market approaches that are struggling to meet the demands of today's digital-first HCPs.
Many organizations, keen to demonstrate progress in digital transformation, have adopted omnichannel initiatives with high expectations, yet often fail to demonstrate success due to data & technology silos and relevance to the customer journey. The difference between mere presence and real engagement lies in the ability to anticipate needs and deliver meaningful interactions in the moments that matter most.
During a recent conversation with a senior executive in one of the big pharma companies, I learned that the organization has invested millions of dollars in an omnichannel platform but is struggling to scale beyond a small number of brands in just one market. Such heavy investments denote the importance and seriousness of omnichannel in pharma today.
I vividly recall the business case we developed back in 2007/08 for the activation of emails and websites under the concept of "Visit without visiting." Obtaining those investments was a challenging endeavor at the time. Forward 18 years, the omnichannel activation has matured tremendously and is a step in the right direction, but many companies are still focused on being present on every channel, integrating channels, and creating content across channels. Undoubtedly, implementation complexity is draining resources and overwhelming HCPs with an excessive amount of generic information, resulting in a lack of engagement or suboptimal customer experience.
As customers' preferences continue to evolve, so do their needs and the complexity of engaging them. Lately, the term "optichannel marketing" has emerged as a popular approach, which describes the practice of selecting the most effective channel for each customer interaction based on data and context. This shift emphasizes the industry's need for more data-driven marketing. This approach represents a fundamental shift from a "presence" mindset to a "precision" mindset. Rather than broadcasting messages across the segments, the optichannel approach utilizes advanced analytics and real-world data to identify the most effective channel and message for each individual at a specific moment. This ensures every interaction is meaningful and effective, significantly reducing wasted marketing spend and improving customer engagement. Here are a few technological advancements and key trends that are driving the move to an optichannel approach:
• Hyper-Personalization with AI and Machine Learning: Moving beyond basic segmentation, AI and ML are now at the core of optichannel strategies. These technologies analyze vast datasets to create dynamic, real-time HCP profiles that consider everything from channel preferences to content consumption patterns. This allows for the delivery of "next-best action" sequences, where each message is a personalized and logical step in a personalized journey.
• Integration of Real-World Data: RWD from sources like claims, access, patient load data, etc., provides a deeper understanding of HCP behaviors and patient journeys. By integrating this data, companies can trigger communications based on specific clinical signals, ensuring the information provided is highly contextual and valuable. For example, an HCP who recently treated a patient with a specific diagnosis could receive an email or a notification with relevant clinical trial data, making the information relevant.
• GenAI Enabling Content at Scale: One of the biggest challenges in personalization is the sheer volume of content required. This "content bottleneck" has limited the pharma's agility and personalization vision. GenAI is emerging as a transformative solution, enabling the industry to produce compliant, high-quality content at an unprecedented scale. GenAI can rapidly prototype drafts, create modular content, and adapt materials for different regions, freeing up teams' bandwidth to focus on strategy and drive personalization at scale.
• Medical Affairs as a Strategic Partner: Optichannel isn't limited to commercial teams. This approach could be a game changer for medical affairs; by leveraging data to understand what an HCP is researching, medical teams can proactively provide unbranded, educational content through the professional's preferred channels, building trust and credibility as a scientific partner.
• Patient-Centric Marketing: A key trend is the move towards patient-centric, outcome-based engagement. Optichannel strategies are not just data-driven but also integrated and are being used to provide personalized support to patients, such as medication reminders or educational content, via their preferred communication channels. This focus on improving patient outcomes demonstrates a deeper commitment to care and strengthens brand loyalty.
Switching to an optichannel approach has benefits, but it's not as simple as it seems, even if it sounds very similar to omnichannel. It is no longer just about activating or integrating new channels; instead, it focuses on establishing a digital central nervous system for customer engagement and agile orchestration, enabling real-time optimization based on previous engagements.
Working with mid-to-large-size life science companies across the globe, the most common problem I have witnessed is a lack of a robust, integrated data foundation, as data silos and fragmented systems can derail even the most promising strategy. To succeed, pharma companies need to invest in the right technology and data platforms to ensure a single, comprehensive view of the customer. A cultural shift is also required, moving teams away from campaign-based thinking toward a continuous, data-driven optimization model. Overcoming "pilot purgatory," where new ideas and technologies are tested but never scaled, requires a commitment to building internal capabilities, establishing the right partnerships, and fostering a culture of agility and learning. The reward is a more efficient, impactful, and ultimately more respectful way of engaging with HCPs and patients in a hyper-connected world.
